Key Documents
Sally Glaser
- Member, Cancer Center
Contact Information
- Clinical Offices
- Academic Offices
Personal Information Email sglaser@nccc.orgAdministrative Contact Email sglaser@nccc.org Tel Work 510-608-5042
Administrative Appointments
- Chief Executive Officer, Northern California Cancer Center , (2009– present )
- Interim Executive Director, Nothern California Cancer Center , (2008– 2009 )
- Director, Greater Bay Area Cancer Registry, Northern California Cancer Center , (2005– present )
- Director, Surveillance Research, Northern California Cancer Center , (2000– 2006 )
Professional Education
- Ph.D., UC Berkeley Epidemiology (1984)
- M.S., UC Berkeley Epidemiology (1978)
- A.B., Harvard College Social Relations (1972)
Web Site Links
Research Interests
Research
Hodgkin lymphoma: Dr. Glaser has conducted numerous descriptive studies in the epidemiology of Hodgkin lymphoma. Her analytic work includes a case-control study of reproductive factors for Hodgkin lymphoma in women that also yielded analyses of numerous additional risk factors and pertinent methodologic issues. Subsequent research has characterized the epidemiologic features of Epstein-Barr virus (EBV)-associated Hodgkin lymphoma. In addition to comparing risk factors for women with and without EBV in their tumors using data from the case-control study, Dr. Glaser examined the epidemiology of EBV-associated Hodgkin lymphoma in a large population-based California case series (n>1,000). With colleagues Dr. Richard Ambinder and Dr. Margaret Gulley, Dr. Glaser also evaluated the reliability of EBV detection assays, generating interpretation guidelines to minimize this variation. Dr. Glaser’s current research interests in Hodgkin lymphoma involve genetic determinants of risk and their interaction with environmental factors.
Breast cancer: Dr. Glaser has been involved in Surveillance Research studies of incidence and survival patterns of breast cancer. Her analytic studies have focused on immune function modulators. These include a population-based study of EBV and risk of breast cancer and subsequent work with Dr. Gulley to develop a comprehensive panel of novel EBV assays to apply to a representative group of breast tumors. Recently Dr. Glaser collaborated with Dr. Henry Erlich to test the hypothesis that racial/ethnic variation in Hodgkin lymphoma genotypes explains some portion of racial/ethnic variation in breast cancer incidence.
Surveillance Research: As Director of Surveillance Research, Dr. Glaser built a research program dedicated to the insightful use of population-based cancer registry data to inform understanding of site-specific cancer incidence and survival patterns in various population subgroups, particularly those defined by race/ethnicity and socioeconomic status. The Surveillance Research group has had particular interest in breast, colon and prostate cancers; lymphomas and other HIV-related malignancies; ovarian cancer; breast cancer in males; and the impact of comorbidity on cancer outcomes. Substantial effort has gone to understanding and improving the quality and completeness of cancer registry variables central to ongoing research interests. New interests include evaluating population demographic trends for their impact on cancer incidence, and examining the influence of the built environment on cancer incidence and outcomes.
Administration
Registry leadership: Dr. Glaser joined the Greater Bay Area Cancer Registry in 1993 to oversee scientific uses of registry data and, in 2005, undertook leadership of the Registry. She and her co-investigator Dr. Dee West are committed to excellence in registry function and to preparing for changes facing cancer registration, including increasing electronic data transmission and expanding data content to include more information on biomarkers, comorbidities and intermediate endpoints such as recurrence.
Publications
- BMC Med. 2009; 31
- Cancer Causes Control. 2009;
- Cancer Causes Control. 2008; (1): 51-7
- Int J Cancer. 2008; (7): 1499-507
- Cancer Causes Control. 2008; (10): 1171-81
- Cancer. 2007; (10): 2100-8
- Leuk Lymphoma. 2007; (2): 223-4
- Cancer Causes Control. 2007; (8): 847-52
- BMC Cancer. 2006; 170
- Cancer Causes Control. 2006; (6): 771-81
- Cancer Epidemiol Biomarkers Prev. 2006; (6): 1095-101
- Cancer Epidemiol Biomarkers Prev. 2006; (4): 630-8
- Cancer Causes Control. 2005; (9): 1009-19
- Cancer Causes Control. 2005; (6): 713-23
- Cancer Epidemiol Biomarkers Prev. 2005; (6): 1441-7
- J Clin Oncol. 2005; (30): 7604-13
- Ann Epidemiol. 2005; (1): 71-9
- Breast Cancer Res. 2005; (2): R184-93
- Diagn Mol Pathol. 2005; (1): 29-33
- Int J Cancer. 2005; (4): 599-605
- Breast Cancer Res Treat. 2005; (2): 145-50
- Ethn Dis. 2004; (2): 292-5
- J Mol Diagn. 2004; (4): 378-85
- Am J Public Health. 2004; (11): 1977-84
- Cancer Causes Control. 2004; (7): 731-9
- Cancer Epidemiol Biomarkers Prev. 2004; (1): 138-43
- Cancer Causes Control. 2004; (3): 243-53
- Cancer Causes Control. 2004; (4): 387-97
- Cancer Epidemiol Biomarkers Prev. 2004; (5): 688-97
- Leuk Lymphoma. 2004; (3): 489-97
- J Acquir Immune Defic Syndr. 2004; (5): 1083-91
- Int J Cancer. 2003; (6): 796-7
- Cancer Causes Control. 2003; (2): 167-74
- Cancer. 2003; (2): 300-9
- Am J Epidemiol. 2003; (6): 553-63
- Arch Intern Med. 2003; (5): 631-2; author reply 632
- Cancer. 2003; (5): 1303-11
- Cancer Epidemiol Biomarkers Prev. 2003; (1): 73; author reply74
- Cancer. 2002; (11): 2836-43
- Ann Epidemiol. 2002; (7): 476-81
- Int J Cancer. 2002; (4): 412-7
- Cancer. 2002; (11): 2268-75
- Breast Cancer Res. 2002; (6): R13
- Am J Epidemiol. 2002; (10): 972-5
- Leuk Res. 2002; (3): 261-9
- Int J Cancer. 2002; (1): 110-7
- Am J Clin Pathol. 2002; (2): 259-67
- Cancer. 2002; (4): 1175-82
- Cancer. 2002; (7): 2015-23
- Ann Epidemiol. 2002; (4): 242-7
- Leuk Lymphoma. 2001 Sep-Oct; (5): 997-1004
- Cancer Causes Control. 2001; (9): 803-12
- Curr Opin Oncol. 2001; (5): 354-9
- Cancer. 2001; (2): 218-24
- Cancer. 2001; (8): 1579-87
- Crit Rev Oncol Hematol. 2000; (1): 27-53
- N Engl J Med. 2000; (5): 358-9
- Am J Epidemiol. 1999; (11): 1063-71
- Ethn Dis. 1998; (2): 218-27
- Biometrics. 1998; (2): 774-81
- Int J Cancer. 1998; (4): 555-8
- J Natl Cancer Inst. 1997; (17): 1311-2
- Ann Epidemiol. 1997; (3): 200-6
- Int J Cancer. 1997; (4): 375-82
- Baillieres Clin Haematol. 1996; (3): 401-16
- Am J Epidemiol. 1995; (8): 856-63
- Am J Epidemiol. 1994; (3): 237-46
- Int J Epidemiol. 1991; (1): 68-75
- Semin Oncol. 1990; (6): 643-59
- Cancer. 1990; (10): 2196-204
- Am J Epidemiol. 1990; (1 Suppl): S167-77
- Cancer. 1987; (11): 2841-7
- J Chronic Dis. 1986; (10): 789-98
- Environ Health Perspect. 1984; 319-32
- Am J Ind Med. 1980; (1): 43-54